Neopharmed Gentili Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
380
- Latest Deal Type
-
Div. Recap.
- (Announced)
- Financing Rounds
-
6
- Investments
-
7
Neopharmed Gentili General Information
Description
Provider of research, development and distribution of medicines to its clients in the national pharmaceutical market. The company's products are in vascular and cardio-metabolic areas, pneumatological areas, antibiotics and supplements, offering clients a tangible impact that crosses multiple therapeutic areas.
Contact Information
Website
www.neogen.itCorporate Office
- Via S.G. Cottolengo, 15
- 20143 Milan
- Italy
Corporate Office
- Via S.G. Cottolengo, 15
- 20143 Milan
- Italy
Neopharmed Gentili Timeline
Neopharmed Gentili Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Neopharmed Gentili Comparisons
Industry
Financing
Details
Neopharmed Gentili Competitors (47)
One of Neopharmed Gentili’s 47 competitors is Genzyme Ireland, a Corporation company based in Kilmeaden, Ireland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Genzyme Ireland | Corporation | Kilmeaden, Ireland | ||||
| Pfizer (Vienna) | Corporation | Vienna, Austria | ||||
| Evonile Pharma | Private Equity-Backed | Mumbai, India | ||||
| Ferrer Internacional | Private Debt Financed | Barcelona, Spain | ||||
| Pfizer Pakistan | Corporation | Karachi, Pakistan |
Neopharmed Gentili Patents
Neopharmed Gentili Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2923701-A1 | Formulation for the treatment and control of metabolic syndrome and correlated disorders | Inactive | 27-Mar-2014 | ||
| ES-8704966-A1 | Cytidine-di:phosphate-choline deriv. prepn. | Inactive | 29-Jan-1986 | ||
| ES-551383-A0 | Procedure for preparing derivatives of citidina-diphosphate-choline. (as a breakdown and with priority of the spanish patent no. 539.891 filed on january 28, 1985) | Active | 29-Jan-1986 | ||
| ES-8609358-A1 | New acylated derivs. of cytidine di:phosphate choline | Inactive | 28-Jan-1985 | ||
| ES-539891-A0 | Procedure for preparing citidine-diphosphate-choline derivatives | Active | 28-Jan-1985 |
Neopharmed Gentili Signals
Neopharmed Gentili Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Neopharmed Gentili Investments & Acquisitions (7)
Neopharmed Gentili’s most recent deal was a Buyout/LBO with BioCryst Pharmaceuticals (European ORLADEYO Business) for . The deal was made on 01-Oct-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| BioCryst Pharmaceuticals (European ORLADEYO Business) | 01-Oct-2025 | Buyout/LBO | Buildings and Property | ||
| Sanofi (Metoclopramide Product Portfolio) | 01-Apr-2025 | Buyout/LBO | Buildings and Property | ||
| Valeas (Pharmaceuticals) | 25-Jul-2022 | Buyout/LBO | Pharmaceuticals | ||
| Bayer (Product Portfolio for Products based on Lormetazepam) | 07-Mar-2022 | Buyout/LBO | Other Pharmaceuticals and Biotechnology | ||
| MDM | 31-Oct-2019 | Buyout/LBO | Therapeutic Devices |
Neopharmed Gentili Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Valeas (Pharmaceuticals) | Milan, Italy | 1934 |
Neopharmed Gentili FAQs
-
When was Neopharmed Gentili founded?
Neopharmed Gentili was founded in 2011.
-
Where is Neopharmed Gentili headquartered?
Neopharmed Gentili is headquartered in Milan, Italy.
-
What is the size of Neopharmed Gentili?
Neopharmed Gentili has 380 total employees.
-
What industry is Neopharmed Gentili in?
Neopharmed Gentili’s primary industry is Pharmaceuticals.
-
Is Neopharmed Gentili a private or public company?
Neopharmed Gentili is a Private company.
-
What is Neopharmed Gentili’s current revenue?
The current revenue for Neopharmed Gentili is .
-
How much funding has Neopharmed Gentili raised over time?
Neopharmed Gentili has raised $1.28B.
-
Who are Neopharmed Gentili’s investors?
Neuberger Berman Group, Renaissance Partners (Italy), and Mediolanum Farmaceutici have invested in Neopharmed Gentili.
-
Who are Neopharmed Gentili’s competitors?
Genzyme Ireland, Pfizer (Vienna), Evonile Pharma, Ferrer Internacional, and Pfizer Pakistan are some of the 47 competitors of Neopharmed Gentili.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process